An Overview of Drug Delivery Nanosystems for Sepsis-Related Liver Injury Treatment
Yi Lu,Yi Shi,Qian Wu,Xin Sun,Wei-Zhen Zhang,Xiao-Ling Xu,Wei Chen
DOI: https://doi.org/10.2147/IJN.S394802
IF: 7.033
2023-02-16
International Journal of Nanomedicine
Abstract:Yi Lu, 1, &ast Yi Shi, 1, &ast Qian Wu, 1 Xin Sun, 1 Wei-Zhen Zhang, 1 Xiao-Ling Xu, 2 Wei Chen 1 1 ICU, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Shulan International Medical College, Zhejiang Shuren University, Hangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wei Chen, ICU, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, 725 South WanPing Road, Shanghai, 200032, People's Republic of China, Tel +86-21-64385700-3522, Email Xiao-Ling Xu, Shulan International Medical College, Zhejiang Shuren University, 8 Shuren Street, Hangzhou, 310015, People's Republic of China, Email Sepsis, which is a systemic inflammatory response syndrome caused by infection, has high morbidity and mortality. Sepsis-related liver injury is one of the manifestations of sepsis-induced multiple organ syndrome. To date, an increasing number of studies have shown that the hepatic inflammatory response, oxidative stress, microcirculation coagulation dysfunction, and bacterial translocation play extremely vital roles in the occurrence and development of sepsis-related liver injury. In the clinic, sepsis-related liver injury is mainly treated by routine empirical methods on the basis of the primary disease. However, these therapies have some shortcomings, such as serious side effects, short duration of drug effects and lack of specificity. The emergence of drug delivery nanosystems can significantly improve drug bioavailability and reduce toxic side effects. In this paper, we reviewed drug delivery nanosystems designed for the treatment of sepsis-related liver injury according to their mechanisms (hepatic inflammation response, oxidative stress, coagulation dysfunction in the microcirculation, and bacterial translocation). Although much promising progress has been achieved, translation into clinical practice is still difficult. To this end, we also discussed the key issues currently facing this field, including immune system rejection and single treatment modalities. Finally, with the rigorous optimization of nanotechnology and the deepening of research, drug delivery nanosystems have great potential for the treatment of sepsis-related liver injury. Keywords: sepsis, liver-injury, drug delivery nanosystems, inflammatory response, oxidative stress, bacterial translocation Sepsis is a life-threatening organ dysfunction resulting from a dysregulated response to infection with high morbidity and mortality. 1 There have been more than 48.9 million new sepsis patients worldwide in each of the past three years, and the number of deaths caused by multiorgan failure is as high as 11 million, accounting for 19.7% of global deaths, which poses a great threat to human health worldwide. 2 The liver is a substantial organ in the human body and is involved in physiological processes such as immunity, metabolism, and detoxification. The liver is one of the most susceptible organs to sepsis. Sepsis-related liver injury (SRLI) refers to liver damage caused directly or indirectly by sepsis, resulting abnormalities in biochemical tests and liver insufficiency, or even liver failure. 3 Liver injury occurs at any stage of sepsis, especially in patients with underlying liver disease. Early detection and intervention can improve patient survival rates to some extent. 4,5 Drug treatment of SRLI is mainly based on conventional empirical methods, including antibiotic, antioxidant, antibacterial, and anti-platelet aggregation treatments. 6–8 These therapies have three main shortcomings. First, many drugs lack either specific targeting to precisely treat damaged tissues or high bioavailability. Small-molecule drugs are rapidly cleared in vivo, which seriously affects drug efficacy. For example, during the development of sepsis, cardiac excretion and intrahepatic blood perfusion are increased and reduced, respectively, resulting in impaired hepatic circulatory metabolism, coagulation dysfunction and microthrombosis. 9 The small-molecule heparin is commonly used clinically to treat platelet aggregation, but its use is limited by a short half-life and difficulty in controlling the dose. 10,11 Second, antibiotics are the standard of clinical care for sepsis; however, the drug resistance and hepatorenal toxicity they cause cannot be ignored, and 70–80% of clinical deaths from sepsis are associated with persistent infection. 12,13 For example, in common neonatal infections. E. coli is resistant to β-lactam antibiotics and aminoglycosides, Group B streptococci are resistant -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology